Abstract:Graft versus host disease (GVHD) is caused by infused donor T cells that primarily target specific organs, such as skin, liver and intestine. While it has been demonstrated that chemokines are critical to directing in vivo trafficking of host-reactive donor T cells into GVHD target organs, blocking GVHD using antagonist antibody (Ab) against chemokine receptors remains an elusive goal. We found that in vivo administration of anti-CXCR3 Ab for 1 week (named short-term treatment) only partially prevented acute GVHD in B6/SJL mice receiving donor C3H.SW naïve CD8+ T cells, with 45% of them dying from the disease. Flow cytometry analysis showed that CXCR3+ CD8+ T cells occurred in the spleens and livers of these GVHD B6/SJL mice by day 3 and peaked by day 7 after transplantation, and persisted throughout the disease course. When donor CXCR3+ CD8+ T cells were recovered from these GVHD B6/SJL recipients at day 14 after transplantation (named day-14 CXCR3+ CD8+ T cells) and adoptively transferred into secondary B6/SJL mice, they caused severe GVHD in these secondary recipients with 90% mortality. Interestingly, short-term treatment using anti-CXCR3 Ab protected 78% of B6/SJL mice receiving these donor day-14 CXCR3+ CD8+ T cells. Thus, besides CXCR3+ T cells, some other pathogenic T cells have developed during GVH reactions. We found that a substantial population of CXCR3− CD8+ T cells occurred by day 14 (termed day-14 CXCR3− CD8+ T cells) after transplantation in the spleens (71.1%) and livers (81.6%) of B6/SJL recipients with ongoing GVHD. As compared to donor day-14 CXCR3+ CD8+ T cells, donor day-14 CXCR3− CD8+ T cells expressed lower levels of CCR2, CCR3, CCR5, CD127, granzyme B and FasL, and produced less IFN-g and TNF-a. Furthermore, adoptive transfer of donor day-14 CXCR3− CD8+ T cells caused delayed onset of GVHD as compared to those recipients of day-14 CXCR3+ CD8+ T cells, with 55% of them dying from the diseases. Prolonged treatment of B6 mice receiving day-14 CXCR3− CD8+ T cells with anti-CXCR3 Ab up to 3 weeks (named long-term treatment) significantly inhibited the development of GVHD. More than 70% of these recipients survived without clinical signs of GVHD. In vivo experiments showed that 23% of day-14 CXCR3− CD8+ T cells were converted into CXCR3+ by 12 hours after adoptive transfer into B6/SJL recipients, and up to 60% by 24 hours. Interestingly, about 25% of CXCR3+ CD8+ T cells were also converted into CXCR3− by 24 hours after their transfer. We found in ex vivo cultures that both dendritic cells and interleukin-2 accounted for this conversion between CXCR3+ and CXCR3− subsets, which was inhibited by addition of Ab specific to MHC-I or CTLA-4 Ig. Taken together, these results suggest that alloantigen-induced repression of chemokine receptor(s) may present a major barrier to the success of GVHD prevention and treatment when using antagonists against chemokines or chemokine receptors.

CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma

CXC Chemokine Receptor 3 Expression on CD34+hematopoietic Progenitors from Human Cord Blood Induced by Granulocyte-Macrophage Colony-Stimulating Factor: Chemotaxis and Adhesion Induced by Its Ligands, Interferon Γ–inducible Protein 10 and Monokine Induced by Interferon Γ

Cxcr3 Expression on Cd34(+) Hemopoietic Progenitors Induced by Granulocyte-Macrophage Colony-Stimulating Factor: Ii. Signaling Pathways Involved

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

Differential expression of granulocyte-macrophage colony-stimulating factor and IL-3 receptor subunits on human CD34+ cells and leukemic cell lines

Cxcr3 Expression and Activation of Eosinophils: Role of Ifn-Gamma-Inducible Protein-10 and Monokine Induced by Ifn-Gamma

An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4

CXCR3 Expression and Activation of Eosinophils: Role of IFN-γ-Inducible Protein-10 and Monokine Induced by IFN-γ1

A Novel Function of Granulocyte Colony-Stimulating Factor in Mobilization of Human Hematopoietic Progenitor Cells

CXC Chemokine Receptor 4 Expression and Stromal Cell‐derived Factor‐1α‐induced Chemotaxis in CD4+ T Lymphocytes Are Regulated by Interleukin‐4 and Interleukin‐10

G-CSF Maintains Controlled Neutrophil Mobilization During Acute Inflammation by Negatively Regulating CXCR2 Signaling

CXCR7 Mediates Neural Progenitor Cells Migration to CXCL12 Independent of CXCR4

Cxcl10 and Cxcr3 regulate self-renewal and differentiation of hematopoietic stem cells

Biological characterization of CD34+ cells mobilized into peripheral blood

CX3CR1 Positively Regulates BCR Signaling Coupled with Cell Metabolism Via Negatively Controlling Actin Remodeling

Gene Expression and Production of the Monokine Induced by IFN-γ (MIG), IFN-Inducible T Cell α Chemoattractant (I-TAC), and IFN-γ-Inducible Protein-10 (IP-10) Chemokines by Human Neutrophils

Recombinant Human Granulocyte Colony-Stimulating Factor Significantly Decreases the Expression of CXCR3 and CCR6 on T Cells and Preferentially Induces T Helper Cells to a T Helper 17 Phenotype in Peripheral Blood Harvests.

Inhibitory Effect of Monoclonal Antibodies Against CXCR3-B NH2-Terminus on the Proliferation of U937 Cells.

Detection of a functional hybrid receptor gammac/GM-CSFRbeta in human hematopoietic CD34+ cells

Differential Regulation of Chemokine Receptor Expressions on T Lymphocyte Subsets in Healthy Donors after Mobilization with Rhg-CSF and Its Correlation with Acute GvHD

[Extracellular HMGB1 Promotes the Migration of Cord Blood CD34⁺ Cells Via SDF-1/CXCR-4 Axis].